Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 275-282

  Lee, Kyung Eun ^a   Chang, Byung Chul ^b   Kim, Han Oll ^a   Yoon, In Kyung ^a   Lee, Na Ra ^a   Park, Hee Yoon ^a   Gwak, Hye Sun ^a  

^a Ewha Womans University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Clearance; CYP4F2; Genotype; Sensitivity; Therapeutic drug monitoring; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CALU GENE; CYP2C19 GENE; CYP2C9 GENE; CYP4F2 GENE; DOSE RESPONSE; DRUG CLEARANCE; DRUG MONITORING; DRUG SENSITIVITY; EPHX1 GENE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GGCX GENE; HEART VALVE PROSTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; SOUTH KOREA; VKORC1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEART VALVE PROSTHESIS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; WARFARIN;

EID: 84861235622     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318256a77c     Document Type: Article

References (39)

1. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126: 457S-482S. (Pubitemid 39297961)
2. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med. 1999; 245:369-374. (Pubitemid 29202215)
3. Bodnar E. A critical assessment of thrombosis and embolism reporting methods. In: Butchart EG, Bodnar E, eds. Thrombosis, Embolism and Bleeding. London: ICR Publishers, 1992:476-484.
4. Wang TL, Li HL, Tjong WY, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta. 2008;396:76-79.
5. Perini JA, Struchiner CJ, Silva-Assunção E, et al. Pharmacogenetics of warfarin: development if a dosing algorithm for Brazilian patients. Clin Pharmcol Ther. 2008;84:722-728.
6. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360: 753-764.
7. Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics. 2008;9:1331-1346.
8. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-4112.
9. Pérez-Andreu V, Roldán V, Antón AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113:4977-4979.
10. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009;10:261-266.
11. Lasker JM, Chen WB, Wolf I, et al. Formation of 20- hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem. 2000;275: 4118-4126. (Pubitemid 30094644)
12. Gebremedhin D, Yamaura K, Harder DR. Role of 20-HETE in the hypoxia-induced activation of Ca2+-activated K+ channel currents in rat cerebral arterial muscle cells. Am J Physiol Heart Circ Physiol. 2008; 294:H2098-H2107.
13. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in vascular system. J Smooth Muscle Res. 2005;41:175-193. (Pubitemid 41596358)
14. Renic M, Klaus JA, Omura T, et al. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2009;29: 629-639.
15. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185. (Pubitemid 34654217)
16. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010; 87:57-64.
17. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87: 445-451.
18. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120:181-186. (Pubitemid 46754413)
19. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433.
20. Ring PR, Bostick JM. Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection. J Pharm Biomed Anal. 2000;22:573-581. (Pubitemid 30151246)
21. Kamas HT, Shiu G, Shah VP. Validation of bioanalytical methods. Pharm Res. 1991;8:421-426.
22. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and g-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103:2630-2635. (Pubitemid 38393017)
23. Cen H, Zeng W, Leng X, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010;70: 234-240.
24. Zhong SL, Yu XY, Liu Y, et al. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genomics. 2011;22: 176-182.
25. Zhang JE, Jorgensen AL, Alfirevic A, et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics. 2009;19:781-789.
26. Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics. 2007;30: 74-81. (Pubitemid 47173292)
27. Fava C, Montagnana M, Almgren P, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in Male Swedes beyond its effect on blood pressure. Hypertension. 2008;52:373-380.
28. Fu Z, Nakayama T, Sato N, et al. A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. Mol Genet Metab. 2009;96:145-147.
29. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status. J Biol Chem. 2002;277:25290-25296. (Pubitemid 34951838)
30. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106:2329-2333. (Pubitemid 41510803)
31. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121: 23-34. (Pubitemid 46421137)
32. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol. 2005;45: 311-333. (Pubitemid 40261808)
33. Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther. 2005;77: 365-372. (Pubitemid 40719265)
34. Wallin R, Hutson SM, Cain D, et al. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J. 2001;15:2542-2544.
35. Wajih N, Sane DC, Hutson SM, et al. The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem. 2004;279:25276-25283. (Pubitemid 38756780)
36. Vecsler M, Loebstein R, Almog S, et al. Combined genetic profiles of components and regulators of the vitamin K-dependent g-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 2006; 95:205-211.
37. Cadamuro J, Dieplinger B, Felder T, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol. 2010;66:253-260.
38. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol. 2007;2:93-106.
39. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trend Pharmacol Sci. 2009;30:375-386.